Pegylated recombinant human insulin (Chongqing Fujin Biomedical)

聚乙二醇化重组人胰岛素(重庆富进生物医药)

Report date: 2025/11/07 20:01:05

Base Information

Drug NamePegylated recombinant human insulin (Chongqing Fujin Biomedical)
Drug Alias NameCA001
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A